FDA grants orphan drug designation to APX005M for three cancer types

The FDA granted orphan drug designation to APX005M for the treatment of three gastrointestinal cancer types, according to the agent’s manufacturer.The designation applies to use of the agent for esophageal, gastroesophageal junction and pancreatic cancers.APX005M (Apexigen) is a humanized monoclonal antibody that targets CD40.The agent is being evaluated in combination with chemotherapy, radiation, immunotherapy or a cancer vaccine for treatment of several malignancies, including esophageal, gastroesophageal junction and pancreatic cancers, as well as melanoma, non-small cell lungRead More

Share on facebook
Share on twitter
Share on linkedin